Robert Finlayson

ACUTE AIDS RETROVIRUS INFECTION

D. A. Cooper, Prudence Maclean, Robert Finlayson et al. · The Lancet · 1985 · 706 citations

Life Sciences, Infectious Diseases, Microbiology +12

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study

Andrew E. Grulich, Rebecca Guy, Janaki Amin et al. · The Lancet HIV · 2018 · 369 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells

Ronald T. Mitsuyasu, Thomas C. Merigan, Andrew Carr et al. · Nature Medicine · 2009 · 263 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +13

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy

Gilbert R. Kaufmann, Mark Bloch, Robert Finlayson et al. · AIDS · 2002 · 169 citations

Life Sciences, Immunology, Infectious Diseases +16